New York State Psychiatric Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, New York State Psychiatric Institute sits in the top decile of US sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count).
New York State Psychiatric Institute: 364 sponsored US clinical trials, 12 recruiting.
New York State Psychiatric Institute sponsors 364 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 296 completed. 80 of these trials are in Phase 3-4 (later-stage) and 152 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 10 trials.
Top-decile sponsor footprint
New York State Psychiatric Institute ranks in the top decile of sponsors by registered trial count (#99 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
296 of 342 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
364 total, page 2 of 8
Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
NCT04056182
Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus
NCT03336398
Imaging the Effects of rTMS on Chronic Pain
NCT02687360
Cannabinoids for Taxane Induced Peripheral Neuropathy
NCT03782402
IPT-A for Adolescents With PTSD Symptoms
NCT03795818
Lorcaserin for Cannabis Use Disorder
NCT03637842
A Pilot Study of SPG Block for PTSD
NCT05743543
Adapting Critical Time Intervention to Support Inpatient Medical Care Transition
NCT03637296
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
NCT03679949
D-serine Augmentation of Neuroplasticity
NCT03711500
An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
NCT03861338
ITI-007 (Lumateperone Tosylate) for Schizophrenia
NCT03817528
18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
NCT03902613
Contact: Developing New Clinical Management Strategies
NCT03812588
L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults
NCT03761030
Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV
NCT03652675
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
NCT03711318
Improving Accessibility and Personalization of CR for Schizophrenia
NCT03576976
Web-based Addiction Treatment: Cultural Adaptation With American Indians
NCT03363256
Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT03321006
Glutamate Reducing Interventions in Schizophrenia
NCT03321617
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
NCT03246113
A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
NCT03389750
Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers
NCT03457077
Pregabalin as Treatment for Alcohol Use Disorder
NCT03256253
Electroretinogram: a New Human Biomarker for Smoking Cessation Treatment
NCT03213418
Computer-Based Treatment for Social Anxiety Disorder
NCT03415022
Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2)
NCT03369249
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment
NCT03205709
Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD
NCT03476902
Effects of Marijuana on Symptoms of OCD
NCT03274440
Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy
NCT03317379
Safety Planning Intervention to Reduce Short Term Risk
NCT03227991
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
NCT03253926
The Anti-Inflammatory Effects of Exercise and Peanut Consumption
NCT03212144
Medication Development for Opioid and Alcohol Abuse
NCT03205423
A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
NCT03232346
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
NCT03113409
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
NCT03169816
Neuroimaging in Patients Undergoing TMS for Depression
NCT02974296
Pilot Study of the Impact of Exercise on Hippocampal Function
NCT03036371
Evaluation of Doxazosin to Alter the Abuse of Oxycodone
NCT03415581
Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients
NCT02913924
Are Bright Lights and Regulated Sleep Effective Treatment for Depression?
NCT03010488
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT02978599
Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression
NCT02943096
Promoting Mother-Baby Bonding Through a Relaxation Routine During Pregnancy
NCT02943083
Facilitating the Behavioral Treatment of Cannabis Use Disorder
NCT02946489
Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder
NCT02932215
Pomaglumetad Effects on Glutamate Biomarkers
NCT02919774
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 101 |
| Phase 3 | 14 |
| Phase 4 | 66 |
Therapeutic Areas
What is open in the New York State Psychiatric Institute pipeline
12 recruiting of 364 indexed (3% open); 296 completed (81%).
Phase mix: 80 late (III/IV) vs 152 early (I/II) (early-phase heavy).
Top condition: Depression (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
New York State Psychiatric Institute: open-pipeline peers nationwide
Peers matched on 364 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
New York State Psychiatric Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 364 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Biotronik · 3% recruiting · 30 trials
- Charles Drew University of Medicine and Science · 3% recruiting · 30 trials
- Kyntra Bio · 3% recruiting · 30 trials
- Halozyme Therapeutics · 3% recruiting · 31 trials
Related
What to do with this New York State Psychiatric Institute page
364 registered trials is a research-attention snapshot, not an endorsement of New York State Psychiatric Institute or any single study.
- 12 of New York State Psychiatric Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition New York State Psychiatric Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. New York State Psychiatric Institute pipeline card: 364 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.